Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Cells · 13.11.2024 · 13 (22) · 1876
DOI: 10.3390/cells13221876 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 13.11.2024. Verfasst von Ahmed Tanvir und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Ajou University School of Medicine, Suwon 16499, Republic of Korea. Hauptthemen laut MEDLINE: Parkinson Disease, Glucose. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Glucose metabolism is essential for the maintenance and function of the central nervous system. Although the brain constitutes only 2% of the body weight, it consumes approximately 20% of the body’s total energy, predominantly derived from glucose. This high energy demand of the brain underscores its reliance on glucose to fuel various functions, including neuronal activity, synaptic transmission, and the maintenance of ion gradients necessary for nerve impulse transmission. Increasing evidence shows that many neurodegenerative diseases, including Parkinson’s disease (PD), are associated with abnormalities in glucose metabolism. PD is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, accompanied by the accumulation of α-synuclein protein aggregates. These pathological features are exacerbated by mitochondrial dysfunction, oxidative stress, and neuroinflammation, all of which are influenced by glucose metabolism disruptions. Emerging evidence suggests that targeting glucose metabolism could offer therapeutic benefits for PD. Several antidiabetic drugs have shown promise in animal models and clinical trials for mitigating the symptoms and progression of PD. This review explores the current understanding of the association between PD and glucose metabolism, emphasizing the potential of antidiabetic medications as a novel therapeutic approach. By improving glucose uptake and utilization, enhancing mitochondrial function, and reducing neuroinflammation, these drugs could address key pathophysiological mechanisms in PD, offering hope for more effective management of this debilitating disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
- Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
- Center for Convergence Research of Neurological Disorders, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
ORCID-Profile: Sang Myun Park
Förderung
- National Research Foundation of Korea
Zitieren
APA
Tanvir, A., Jo, J., & Park, S. M. (2024). Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease. Cells, 13(22), 1876. https://doi.org/10.3390/cells13221876
Vancouver
Tanvir A, Jo J, Park SM. Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease. Cells. 2024;13(22):1876. doi:10.3390/cells13221876
BibTeX
@article{Tanvir2024,
author = {Tanvir, Ahmed and Jo, Junghyun and Park, Sang Myun},
title = {Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease},
journal = {Cells},
year = {2024},
volume = {13},
number = {22},
pages = {1876},
doi = {10.3390/cells13221876}
}
EUVIMED